JAK Inhibitor Stays Effective Beyond 1 Year for Giant Cell Arteritis

By News Health
1 hour Ago

(MedPage Today) — CHICAGO — Treatment of giant cell arteritis (GCA) with the oral drug upadacitinib (Rinvoq) was durably effective when continued for 2 years, results from a phase III trial extension indicated.
Some 85% of patients remained…

Source link : https://www.medpagetoday.com/meetingcoverage/acr/118147

Author :

Publish date : 2025-10-26 21:12:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

'If That Doesn’t Blow Your Mind': What We Heard This Week

Tirzepatide-Hormone Therapy Combo Tied to Weight Loss in Postmenopausal Women

Prevention Has a Branding Problem

Pool Data Back Safety of Newly Approved Non-Hormonal Treatment for Hot Flashes

What Vaccine Was Tied to Longer Cancer Survival?

PFAS Exposure and Brain Development; Food Insecurity and Blood Pressure